P450
[용어속성] Enzyme
ADME and Pharmacokinetic Properties of Remdesivir: Its Drug Interaction Potential
Review
[키워드] activated
ADME
antiviral activity
beta coronavirus
Carboxylesterases
caused
clinician
Comorbidities
Complication
coronavirus 2
COVID-19
COVID-19 patients
COVID-19 treatment guideline
cytochrome P450
distribution
domain
drug
drug interaction
drug regimen
drug-drug interaction
Ebola virus
enzyme
evaluated
future work
global pandemic
Healthcare systems
information
lack
medication
metabolism
metabolite
nucleotide
P450
pandemic
pharmacokinetics
Potential
Prevent
property
Remdesivir
Replication
reported
respiratory
RNA
SARS-CoV-2
tested
the SARS-CoV-2
therapeutic
transporter
Treatment
treatment regimens
WHO
World Health Organization
[DOI] 10.3390/ph14070655 PMC 바로가기 [Article Type] Review
[DOI] 10.3390/ph14070655 PMC 바로가기 [Article Type] Review
Therapy with lopinavir/ritonavir and hydroxychloroquine is associated with acute kidney injury in COVID-19 patients
로피나비르/리토나비르 및 하이드록시클로로퀸을 사용한 치료는 COVID-19 환자의 급성 신장 손상과 관련이 있습니다
Research Article
[키워드] Acute kidney injury
acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
Affect
AKI
Analysis
analyzed
Antiviral agents
both groups
Care
control group
controls
coronavirus
coronavirus disease
correlation
COVID-19
COVID-19 patient
COVID-19 patients
creatinine
CYP3A4
cytochrome P450
enzyme
Germany
Hospitalized
Hydroxychloroquine
ICU
ICU patient
ICU Patients
in both group
in vitro activity
incidence
increase in
independent risk factor
Interaction
Kidney function
Kidney injury
linear
linear correlation
Lopinavir
Lopinavir/ritonavir
mechanism
Mortality
National Early Warning Score
NEWS
non-ICU
non-ICU patients
P450
Patient
patients
R 2
receiving
respiratory
Result
Ritonavir
SARS-CoV-2
score
serum creatinine
severe acute respiratory syndrome Coronavirus
severely ill COVID-19 patients
severity
severity of illness
Standard therapy
therapy
treated
Treatment
treatment of COVID-19
university
university hospital
was performed
with COVID-19
[DOI] 10.1371/journal.pone.0249760 PMC 바로가기 [Article Type] Research Article
[DOI] 10.1371/journal.pone.0249760 PMC 바로가기 [Article Type] Research Article
Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 Therapies
향정신성 제제와 용도 변경 COVID-19 치료제 간의 임상적으로 중요한 약물 상호작용
Review
[키워드] acting
agent
clinically
concomitant use
COVID-19
COVID-19 therapy
cytochrome P450
drug
drug interaction
Drug interactions
drug-drug interaction
expected
infected with COVID-19
Interaction
management
Manifestations
mechanism
P450
Patient
pharmacogenetic
pharmacokinetic
polymorphism
Polymorphisms
Psychiatric
psychiatric disorder
Psychiatric disorders
Psychotropic
psychotropic agent
psychotropic agents
Psychotropic medication
psychotropic medications
raise
recommendation
responsible
resulting
severity
severity of illness
Significant
Stage
subject
synergistic
Therapies
therapy
Toxicity
[DOI] 10.1007/s40263-021-00811-2 PMC 바로가기 [Article Type] Review
[DOI] 10.1007/s40263-021-00811-2 PMC 바로가기 [Article Type] Review
Drug-drug interactions between COVID-19 treatments and antipsychotics drugs: integrated evidence from 4 databases and a systematic review
COVID-19 치료제와 항정신병 약물 간의 약물-약물 상호작용: 4개 데이터베이스의 통합 증거 및 체계적인 검토
Article
[키워드] Agitation
Anakinra
Anxiety
Azithromycin
benefit
can be used
can not
caution
Chloroquine
chlorpromazine
clozapine
Combination
conducted
Confusion
Consensus
coronavirus
coronavirus disease
COVID-19
COVID-19 treatment
COVID-19 treatments
database
delirium
drug
drug interaction
drug-drug interaction
Drug-drug interactions
Effects
Evidence
except for
Favipiravir
group
hematological
Hydroxychloroquine
Indinavir
information
Interaction
interactions
list
Lopinavir
Lopinavir/ritonavir
medication
P450
patient safety
pharmacological management
provide
Psychopharmacotherapy
QT prolongation
quetiapine
recommendation
Remdesivir
risk
risperidone
Ritonavir
Safe
searched
side
Side effects
solution
systematic review
Therapies
Tocilizumab
Torsade de Pointes
Treatment
treatments for COVID-19
with COVID-19
[DOI] 10.1007/s00213-020-05716-4 PMC 바로가기 [Article Type] Article
[DOI] 10.1007/s00213-020-05716-4 PMC 바로가기 [Article Type] Article
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial
Letter
[키워드] 1:1
24 hour
Ability
absence
accompany
activity
Administered
administration
Admission
adverse events
Affect
age
alkaline phosphatase
allergy
ALT
alternative hypothesis
ambient
Analysis
ANC
Anti-inflammatory
anticipated
antipyretics
antivirals
Arm
ARMS
assumed
AST
Baltimore
baseline
benefit
blinded
block
block randomization
Blood
breastfeeding women
Bronchoalveolar lavage
calculated
Care
Cellulose
center
Chest
chest X-ray
childbearing potential
clinical
clinical condition
Clinical course
clinical impact
Clinical improvement
Clinical outcome
clinical status
clinical trial
collected
competing
Compliance
concealed
Concentration
Concomitant
conditions
conducted
congestive heart failure
Contraception
Control
control arm
Conventional
Corticosteroids
COVID-19
COVID-19 disease
COVID-19 infection
COVID-19 pandemic
criteria
criterion
Critical
CT scan
current
Day
Declaration of Helsinki
decrease
defined
detect
direct bilirubin
disease
disorder
dissemination
dose
double-blind
drug
Drug administration
drug-drug interaction
drugs
Duration
ECMO
Efficacy
Efficacy and safety
element
eligible
endosomal pH
Enrollment
ethnic group
evaluate
Evidence
exclusion
expected
exploratory endpoint
extracorporeal membrane oxygenation
Face mask
FDA
Fisher
Good
group
handling
harmonization
hematologic
histocompatibility complex
Hospitalization
Hospitalized
hospitalized patient
Hydroxychloroquine
Hypothesis
ICU
IL-6 levels
Imatinib
immunomodulatory
immunomodulatory drugs
IND
information
Informed consent
inhibitory activity
intensive care
intensive care unit
intention to treat
interfere
International Conference
invasive
Invasive mechanical ventilation
investigational agent
investigator
ITT
Laboratory
Last
limit
limitation
liver
Local
lysosomal sequestration
magnitude
matching placebo
mechanical ventilation
men and women
MHC
mononuclear cell
Mortality
nasal
nasopharyngeal
Nasopharyngeal swab
neutrophil count
New
new oxygen use
non-invasive ventilation
non-rebreather mask
not blinded
null hypothesis
number
objective
off-label
off-label use
Oropharyngeal
outcome
outcomes
oxygen
Oxygenation
P450
packaged
PaO
participant
Participants
Patient
patients
patients with ARDS
patients with COVID-19
PBMCs
performed
Pharmacist
Pharmacy
phase 3 study
Placebo
placebo-controlled
Pneumonia
positive COVID-19
Practice
primary analysis
primary endpoint
principal
progression
proportion
protocol
Psychiatric
Radiographic
random number generator
randomised controlled trial
randomization
Randomized
Randomized controlled trial
receive
receiving
recruitment
Regulatory
renal dysfunction
renal replacement therapy
replication of SARS-CoV-2
required
requiring supplemental oxygen
Respiratory illness
respiratory tract
risk
RT-PCR
Safety
Sample size
sarilumab
SARS-CoV
SARS-CoV-2
secondary endpoint
Seizure
Serious Adverse Events
service
severe disease
severity
significance level
Site
Society
stability
Standard of care
status
stratified
study drug
study enrollment
study outcomes
Study protocol
subject
submitted
supplemental oxygen
Support
Suspension
symptomatic
Tablet
temperature
Test
the patient
the primary endpoint
time
TKI
TKI-induced attenuation of vascular leak
TKI-induced prevention and treatment lung inflammation
Tocilizumab
transcriptomics
Treatment
treatment allocation
treatment arm
treatments for COVID-19
Trial
two-sided
tyrosine kinase inhibitor
uncontrolled
university
unstable angina
vasopressors
ventilator
ventilator free days
viral ABL-1 signalling
website
with COVID-19
[DOI] 10.1186/s13063-020-04819-9 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04819-9 PMC 바로가기 [Article Type] Letter
Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial)
증상이 있는 SARS-CoV-2 감염(COVID-19)이 있는 고령자의 가정 치료: 여러 가지 실험적 치료의 효능과 내약성을 평가하기 위한 MAMS(Multi-Arm Multi-Stage) 무작위 시험에 대한 연구 프로토콜의 구조화된 요약 65세 이상 외래 환자의 입원 또는 사망 위험 감소(COVERAGE 시험)
Letter
[키워드] 6-mercaptopurine
Abnormalities
ACEi
added
age
amodiaquine
Analysis
antrafenine
approved
ARB
ARBs
Arm
azathioprine
Blinding
Bordeaux
Caregivers
Chloroquine
chronic hepatitis
Chronic kidney disease
citalopram
clinical
Colitis
Combination
comparator
complex
conducted
Control
control arm
COVID-19
COVID-19 pandemic
criteria
CYP3A4
cytochrome P450
Dasatinib
death
Dementia
dialysis
dissemination
Domperidone
drug
Duchy
Efficacy
element
enrolled
enrolment
Enterocolitis
escitalopram
EudraCT
Evidence
exclusion criteria
experimental arm
experimental drug
Experimental drugs
Favipiravir
feasibility
Final
final analysis
first symptom
first symptoms
floctafenine
France
French
futility
galactose
GFR
glafenine
Glucose
Glucose-6-phosphate
glucose-6-phosphate dehydrogenase
glucose-6-phosphate dehydrogenase deficiency
Grand duchy
halofantrine
Health Insurance
heart rate
hepatic
Hepatic porphyria
home
hospital
hospitalisation
Hydroxychloroquine
hydroxyzine
hypersensitivity
Hyperuricemia
Ileus
Imatinib
immunological
incidence
Inclusion
increase in
inducer
inhibitor
Interim analyses
interim analysis
intervals
investigator
investigators
Isoenzyme
Kidney disease
Lactase
Lactose
liver failure
Long
Long QT syndrome
Luxembourg
malabsorption
mefloquine
mercaptopurine
metabolism
multi
multi-arm
nasopharyngeal
Nasopharyngeal swab
New
Nilotinib
not blinded
number
nursing home
nursing homes
objective
Older
Open-label
open-label trial
other treatment
other treatments
outcome
Outpatient
P450
Paris
participant
Patient
performed
phase
Piperaquine
Positive test
Prevent
primary care
Primary outcome
proportion
protocol
pyrazinamide
QTc interval
randomisation
randomised
Randomized
Randomly
receive
recruited
Region
Registered
regulatory authority
repaglinide
replaced
REPLACED BY
reported
Repurposed drug
residence
Safety Monitoring Board
Sample size
SARS-CoV-2
SARS-COV-2 infection
scale
Stage
Standard
statistician
statisticians
status
stratified
Study protocol
submitted
symptomatic SARS-CoV-2 infection
Tablet
telmisartan
tested
theophylline
Toxicity
Trace element
trace elements
treated
Treatment
treatment arm
Trial
Trial registration
Version
virus
Virus Disease
Vitamin
vitamins
Warfarin
[DOI] 10.1186/s13063-020-04619-1 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04619-1 PMC 바로가기 [Article Type] Letter
Genetic Polymorphisms Complicate COVID-19 Therapy: Pivotal Role of HO-1 in Cytokine Storm
Review
[키워드] ACE
ACE-2
ACE-2R
acute respiratory distress
Affect
Angiotensin converting enzyme-2
Antiviral
baseline
bind
cause
Cell
chronic inflammatory disease
common cold
coronavirus
COVID-19
current
CYP2D6
cytochrome P450
cytokine level
Cytokine storm
Cytokines
disease
Ebola
Enzymes
Genetic polymorphism
genetic polymorphisms
global pandemic
HIV
HO-1
Human immunodeficiency virus
include
Inflammatory response
kidney
Lungs
majority
manifested
medication
MERS
Middle East
mitochondrial dysfunction
organ
P450
patients with obesity
porphyrins
reactive oxygen specy
receptor
reservoir
resulting
RNA virus
role
SARS-CoV-2
Spread
storm
subsequent
syndrome
systemic inflammatory response
therapy
Treatment
upregulation
virus
white adipose tissue
[DOI] 10.3390/antiox9070636 PMC 바로가기 [Article Type] Review
[DOI] 10.3390/antiox9070636 PMC 바로가기 [Article Type] Review
Impact of pantoprazole on absorption and disposition of hydroxychloroquine, a drug used in Corona Virus Disease-19 (Covid-19): A structured summary of a study protocol for a randomised controlled trial
Letter
[키워드] 1:1
Absorption
administration
All participant
anticipated
Area
assigned
AUC
C max
center
changes in
clinical
Concentration
control group
Corona
Course
COVID-19
CYP2D6
CYP3A4
dissemination
dose
drug
drug-drug interaction
element
enrolment
enzyme activity
Enzymes
EudraCT
Germany
HCQ
Hydroxychloroquine
Impact
inhibitor
investigator
Microdosing
Midazolam
mononuclear cell
not blinded
number
objective
Open-label
outcome
P450
Pantoprazole
parallel group
participant
Patient
PBMC
PBMCs
performed
Peripheral blood
Phase I
plasma
PPI
probe
protocol
randomisation list
randomised
randomised controlled trial
Randomized
receive
recruitment
Registered
registry
reported
Sample size
secondary
single dose
Standard
status
Study protocol
target cell
treated
treatment group
Trial
trial protocol
Two-arm
university
Volunteer
website
Whole blood
Yohimbine
[DOI] 10.1186/s13063-020-04476-y PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04476-y PMC 바로가기 [Article Type] Letter
Treatment concerns for psychiatric symptoms in patients with COVID-19 with or without psychiatric disorders
Editorial
[키워드] Antipsychotics
Antiviral
antiviral drugs
Combination
coronavirus
develop
drug interactions and side-effects
infected with COVID-19
interactions
P450
Patient
patients with COVID-19
Psychiatric
psychiatric disorder
psychotic disorders
Safe
Symptom
Tolerability
Treatment
[DOI] 10.1192/bjp.2020.84 PMC 바로가기 [Article Type] Editorial
[DOI] 10.1192/bjp.2020.84 PMC 바로가기 [Article Type] Editorial